Log In
BCIQ
Print this Print this
 

IONIS-HBVRx (formerly ISIS-GSK3Rx, ISIS-HBVRx)

  Manage Alerts
Collapse Summary General Information
Company Ionis Pharmaceuticals Inc.
DescriptionAntisense oligonucleotide targeting HBV RNA
Molecular Target
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat HBV infection; Treat viral infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,500.0M

$35.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/31/2010

$1,500.0M

$35.0M

Undisclosed

Get a free BioCentury trial today